A Phase 2B Randomized, Placebo Controlled, Double Blind Clinical Trial of EPI-743 in Children With Genetically Confirmed Leigh Syndrome

Trial Profile

A Phase 2B Randomized, Placebo Controlled, Double Blind Clinical Trial of EPI-743 in Children With Genetically Confirmed Leigh Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Vatiquinone (Primary)
  • Indications Leigh disease
  • Focus Therapeutic Use
  • Sponsors Edison Pharmaceuticals
  • Most Recent Events

    • 18 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 12 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top